Guilford Street Laboratories

We’re #hiring a new Senior Scientist in London Area, United Kingdom. Apply today or share this post with your network.

🎄✨ Merry Christmas and Happy New Year from all of us at Guilford Street Laboratories! ✨🎄 As we celebrate this festive season and ring in 2025, we want to take a moment to reflect on what an incredible year 2024 has been for GSL. We are so grateful for everything we've achieved together and are beyond excited about what lies ahead in 2025. Let's continue to push boundaries, embrace new opportunities, and create an even brighter future. Wishing you and your loved ones a joyous Christmas and a prosperous New Year filled with success, health, and happiness. Here's to another amazing year! 🥂 #MerryChristmas #HappyNewYear #2025 #Innovation #TeamGSL

Guilford Street Laboratories is proud to announce that we have been awarded a #RegulatoryAffairs grant through the MedTech Accelerator Rapid Regulatory Support (MARRS) Programme - delivered by CPI in partnership with the Office of Life Sciences (Department for Science, Innovation and Technology). This grant will support our efforts to navigate the complex and evolving regulatory landscape for #Diagnostics, #MachineLearning, and #Biomarker technologies. With this funding, we can accelerate the development and delivery of our innovative, compliant medical devices—bringing safer and more effective solutions to market faster. #MedTech #Innovation #RegulatorySupport 🔬

Experienced in triple quadrupole mass spec and fancy getting involved in the translation of new, state-of-the-art tests into the clinic and NHS, come work with us.

🚀 Big news from Guilford Street Laboratories! We’re thrilled to announce that we've been awarded an Arm’s-Length Medical Grant from Chiesi UK to bring our groundbreaking ImmunoTADA platform into clinical practice! 🙌 ImmunoTADA is the world’s first mass spectrometry-based system designed to quantify, subclass, and isotype immune responses to enzyme replacement therapies (ERT) and AAV gene therapy vectors. This innovative platform offers unmatched sensitivity, rapid turnaround times, and critical insights that empower clinicians to make personalized, data-driven treatment decisions—a true game-changer for rare disease management. 🎙️ As Dr. Tomas Baldwin, our CEO, puts it: “This represents a paradigm shift in how we monitor and understand immune responses to advanced therapies. Clinicians and patients alike will benefit from tailored treatment decisions driven by actionable insights.” We look forward to collaborating with healthcare institutions and clinical leaders to shape the future of optimized care in complex therapeutic landscapes. 🌟 Read the full press release here: https://lnkd.in/e9muC7JU #Innovation #PrecisionMedicine #RareDiseases #Immunology #AdvancedTherapies

How do you keep FDA submissions on track under pressure? Guilford Street Laboratories faced a one-day turnaround on an FDA query during their journey to Breakthrough Designation for PD Predict. With Hardian’s support, they met the challenge head-on, ensuring every detail aligned with regulatory requirements. Seamless collaboration and precise documentation made all the difference, streamlining the process from start to finish. Need a partner to navigate your next regulatory milestone? Contact Hardian today ➡️ https://lnkd.in/ecUMAN9t #HardianHealth #Regulation #Startups #HealthTech #DigitalHealth

It has been a pleasure to work with Hardian Health on securing FDA Breakthrough Device Designation for PD Predict - our proteomic blood test for Parkinson's disease. The support received from the team at Hardian has greatly accelerated GSL through to this significant milestone in the development of PD Predict, and we look forward to continuing to collaborate as we move towards full regulatory submission. Full story detailed below. #GSL #Parkinsonsdisease #FDA #breakthrough #proteomics #bloodtest

There are some really exciting things coming up with GSL across our cardiomyopathy, neuro and immuno programmes. As such, the team will be expanding! We are on the look out for mass spec specialists, particularly those with an analytical method development background. If you're interested in joining the team, or if you know someone who might be, take a look at the below!

More Exciting News at GSL! We’re thrilled to welcome Jenny Hällqvist as our new Machine Learning Lead! 🎉 Jenny is a true expert in developing machine learning models for biomarker test development. Her groundbreaking contributions were instrumental in the creation of PD Predict, our innovative blood-based diagnostic test for Parkinson’s disease. We’re excited to see how Jenny’s expertise will drive innovation and strengthen our capabilities in ML-driven diagnostics. The future looks bright! 🌟 #WelcomeJenny #MachineLearning #Innovation #Healthcare #PDpredict #Teamwork #GSL

🚀 Exciting News at GSL! We’re pleased to welcome Ed Critchley to the board as our new Chief Commercial Officer! 🎉 Ed brings extensive experience in driving commercial success across multiple sectors, including his impactful work with our sister company, MyCardium AI. His strategic insights and leadership will be instrumental in shaping the future of GSL, alongside his ongoing work with Mycardium. We’re looking forward to seeing the value Ed will add to the team. Exciting times ahead! 🌟